-transparent.png){kind=logo}
OBJECTIVE To identify which activities produced a significant improvement in blood pressure control in patients with type 2 diabetes when pharmacists were added to primary care teams. METHODS This prespecified, secondary analysis evaluated medication management data from a randomized controlled trial. The primary outcome was a change in treatment, defined as addition, dosage increase, or switching of an antihypertensive medication during the 1-year study period. The secondary outcome was a change in antihypertensive medication adherence using the medication possession ratio (MPR). RESULTS The 200 evaluable trial patients had a mean age of 59 (SD, 11) years, 44% were men, and mean blood pressure was 130 (SD, 16)/74 (SD, 10) mm Hg at baseline. Treatment changes occurred in 45 (42%) of 107 patients in the intervention group and 24 (26%) of 93 patients in the control group (RR, 1.63; 95% CI, 1.08-2.46). Addition of a new medication was the most common type of change, occurring in 34 (32%) patients in the intervention group and 17 (18%) patients in the control group (P = 0.029). Adherence to antihypertensive medication was high at baseline (MPR, 93%). Although medication adherence improved in the intervention group (MPR, 97%) and declined in the control group (MPR, 91%), the difference between groups was not significant (P = 0.21). CONCLUSIONS The observed improvement in blood pressure control when pharmacists were added to primary care teams was likely achieved through antihypertensive treatment changes and not through improvements in antihypertensive medication adherence.
Dima Omran, and
Sumit R Majumdar, and
Jeffrey A Johnson, and
Ross T Tsuyuki, and
Richard Z Lewanczuk, and
Lisa M Guirguis, and
Mark Makowsky, and
Scot H Simpson
June 1998,
The Annals of pharmacotherapy,
Dima Omran, and
Sumit R Majumdar, and
Jeffrey A Johnson, and
Ross T Tsuyuki, and
Richard Z Lewanczuk, and
Lisa M Guirguis, and
Mark Makowsky, and
Scot H Simpson
January 2011,
Diabetes care,
Dima Omran, and
Sumit R Majumdar, and
Jeffrey A Johnson, and
Ross T Tsuyuki, and
Richard Z Lewanczuk, and
Lisa M Guirguis, and
Mark Makowsky, and
Scot H Simpson
January 2013,
The Annals of pharmacotherapy,
Dima Omran, and
Sumit R Majumdar, and
Jeffrey A Johnson, and
Ross T Tsuyuki, and
Richard Z Lewanczuk, and
Lisa M Guirguis, and
Mark Makowsky, and
Scot H Simpson
May 2021,
Journal of diabetes science and technology,
Dima Omran, and
Sumit R Majumdar, and
Jeffrey A Johnson, and
Ross T Tsuyuki, and
Richard Z Lewanczuk, and
Lisa M Guirguis, and
Mark Makowsky, and
Scot H Simpson
January 2017,
Journal of the American Pharmacists Association : JAPhA,
Dima Omran, and
Sumit R Majumdar, and
Jeffrey A Johnson, and
Ross T Tsuyuki, and
Richard Z Lewanczuk, and
Lisa M Guirguis, and
Mark Makowsky, and
Scot H Simpson
August 2017,
The Nurse practitioner,
Dima Omran, and
Sumit R Majumdar, and
Jeffrey A Johnson, and
Ross T Tsuyuki, and
Richard Z Lewanczuk, and
Lisa M Guirguis, and
Mark Makowsky, and
Scot H Simpson
August 2017,
The Nurse practitioner,
Dima Omran, and
Sumit R Majumdar, and
Jeffrey A Johnson, and
Ross T Tsuyuki, and
Richard Z Lewanczuk, and
Lisa M Guirguis, and
Mark Makowsky, and
Scot H Simpson
January 2016,
Diabetes & metabolic syndrome,
Dima Omran, and
Sumit R Majumdar, and
Jeffrey A Johnson, and
Ross T Tsuyuki, and
Richard Z Lewanczuk, and
Lisa M Guirguis, and
Mark Makowsky, and
Scot H Simpson
February 2007,
The Medical journal of Australia,
Dima Omran, and
Sumit R Majumdar, and
Jeffrey A Johnson, and
Ross T Tsuyuki, and
Richard Z Lewanczuk, and
Lisa M Guirguis, and
Mark Makowsky, and
Scot H Simpson
October 2018,
Australian journal of general practice,
